The sale enhances Certara's focus on its higher-margin MIDD and clinical intelligence business; monitor updated 2026 guidance post-closing for revised financial outlook and reinvestment plans.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 22 $6.38entry
- T+1 · 7mo ago −5.96%α −5.56% · $6.00
- T+5 · 7mo ago −4.23%α −4.29% · $6.11
- T+20 · 6mo ago −28.06%α −31.22% · $4.59
- T+60 · 4mo ago +8.62%α +3.84% · $6.93
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Certara agreed to sell its regulatory and medical writing business to Veristat for up to $135 million in cash, consisting of $100 million upfront and up to $35 million in earn-outs. The move sharpens focus on its core Model-Informed Drug Development (MIDD) platform and is expected to close in Q2 2026.
Key Financial Metrics
Key Facts
- Certara is selling its regulatory and medical writing business to Veristat
- Total consideration is up to $135 million: $100 million upfront cash and $35 million in contingent earn-outs
- The business generated $50 million in revenue and $17 million in adjusted EBITDA in 2025
- Transaction expected to close in Q2 2026, subject to customary conditions
- Proceeds will be used to accelerate investment in Certara's MIDD platform
Financial Impact
Up to $135 million in proceeds, including $35 million contingent on performance; divests a $50 million revenue business
Risk Factors
- Transaction may not close due to customary closing conditions
- Loss of $50 million in annual revenue and associated EBITDA from the divested business
- Execution risk in redeploying proceeds to drive growth in core platform
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (CERT), Batch item 1 | 0001104659-26-046358 |
| Document: tm2612400d1_ex99-1.htm | press-3278796 |
| Document: 0001104659-26-046358-index-headers.html | 0001104659-26-046358 |
| Document: 0001104659-26-046358-index.html | 0001104659-26-046358 |
| Document: 0001104659-26-046358.txt | 0001104659-26-046358 |
| PRESS-RELEASE Data (Synthetic) | 0001104659-26-046358 |
Track record
14 reports on CERT
4 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +51.56% at T+60 after the Aug 15, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 9, 20267d ago Institutional Cluster Mixed 3/10 Entry $12.22 to $12.13 Now $11.39 −6.79% ▼ −0.78% −0.41% vs SPY
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $12.18 to $12.05 Now $11.39 −6.49% ▼ −1.07% −1.38% vs SPY
- Aug 15, 202613w ago Institutional Cluster Bullish 5/10 Entry $8.00 to $8.01 Now $11.39 +42.38% ▲ +0.13% +0.80% vs SPY
- Aug 4, 202614w ago 8-K Neutral 2/10 Entry $7.80 to $8.01 Now $11.39 +46.03% ▲ +2.69% +2.89% vs SPY
- Jul 15, 202617w ago Press Release Neutral 1/10 Entry $7.28 to $6.93 Now $11.39 +56.46% ▼ −4.81% −3.82% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bearish 6/10 Entry $5.27 to $5.20 Now $11.39 −116.13% ▲ +1.33% +1.87% vs SPY
- May 11, 202627w ago 8-K Bearish 6/10 No price data
- May 11, 202627w ago Press Release Bearish 7/10 Entry $5.13 to $5.09 Now $11.39 −122.03% ▲ +0.78% +0.64% vs SPY
- Apr 22, 202629w ago 8-K / PRESS-RELEASE Bullish 7/10 Viewing Entry $6.38 to $6.00 Now $11.39 +78.53% ▼ −5.96% −5.56% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers